Prognosis in amyotrophic lateral sclerosis

Aguila, Michael A. Del; Longstreth, W. T.; McGuire, Valerie; Koepsell, Thomas D.; Belle, Gerald van

doi:10.1212/01.wnl.0000049472.47709.3b

Cited by 403 publications

(356 citation statements)

References 52 publications

Supporting

Mentioning

287

Contrasting

Unclassified

Order By: Relevance

“…A myotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by rapidly progressive paralysis leading to death from respiratory failure. Population-based epidemiological studies indicate that the median survival of ALS patients is 20-36 mo (1)(2)(3). Demographic and clinical features, as well as riluzole and certain symptomatic therapies, are known to modestly modify survival, but the influence of genetics on the rate of disease progression and survival is not known (4).…”

mentioning

confidence: 99%

Kinesin-associated protein 3 (KIFAP3) has no effect on survival in a population-based cohort of ALS patients

Traynor¹,

Nalls

Lai

et al. 2010

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

It was recently reported that rs1541160 on chromosome 1q24.2 has a marked effect on survival of amyotrophic lateral sclerosis (ALS) patients by influencing KIFAP3 expression. The cohorts used in that study were collected from ALS specialty clinics. We attempted to replicate these findings in a population-based cohort of 504 Italian ALS patients. None of 140 SNPs genotyped within the KIFAP3 locus (including rs1541160) had an effect on survival (log-rank P value for rs1541160 = 0.47) or on gene expression in that region. These data illustrate the complexities associated with analyzing ALS phenotypes for association. A myotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by rapidly progressive paralysis leading to death from respiratory failure. Population-based epidemiological studies indicate that the median survival of ALS patients is 20-36 mo (1-3). Demographic and clinical features, as well as riluzole and certain symptomatic therapies, are known to modestly modify survival, but the influence of genetics on the rate of disease progression and survival is not known (4). Landers et al. (5) recently reported that the CC genotype of SNP rs1541160 within the kinesin-associated protein 3 (KIFAP3) gene on chromosome 1q24.2 conferred a 14-mo survival advantage on ALS patients. Furthermore, expression data based on 26 occipital lobe brain samples suggested that the CC genotype of this SNP reduced KIFAP3 expression by 41% compared with the TT genotype (5). To confirm the accuracy of this report, we attempted to replicate this finding in a population-based cohort of 504 Italian ALS patients collected using the Piemonte and Valle d'Aosta Registry for ALS (PARALS). We also evaluated the effect of the identified SNP, and all SNPs within the 1-Mb surrounding region, on the expression of KIFAP3 in four brain regions obtained from 144 neurologically normal individuals. ResultsRs1541160 had no effect on survival in our population-based cohort of 504 Italian ALS cases either under the genotypic model [median survival for CC genotype = 4.09 y; CT genotype = 3.48 y; TT genotype = 3.58 y; log-rank P = 0.48, Peto P = 0.60 (Fig. 1A)] or under the allelic model [log-rank P = 0.33, Peto P = 0.53 (Fig. 1B)]. Similarly, survival analysis limited to the 318 deceased ALS patients failed to demonstrate an effect of rs1541160 on survival either under the genotypic model [log-rank P = 0.55, Peto P = 0.92 (Fig. 1C)] or under the allelic model [log-rank P = 0.42, Peto P = 0.71 (Fig. 1D)]. Linear regression modeling of the deceasedonly cohort, incorporating age, gender, site of symptom onset, and population structure (component vectors 1 and 2 from multidimensional scaling) as covariates, was also not significant (β coefficient = 0.024, P = 0.89). Survival analysis limited to the cohort of patients attending a specialized ALS clinic was similarly negative [n = 89 patients (Fig. S1)]. None of the 139 other SNPs within the 1-Mb region surrounding KIFAP3 significantly influenced survival of the Italian ALS cohort (...

show abstract

mentioning

confidence: 99%

Kinesin-associated protein 3 (KIFAP3) has no effect on survival in a population-based cohort of ALS patients

Traynor¹,

Nalls

Lai

et al. 2010

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

show abstract

“…41 The prevalence of current smoking (24%) among our cases was also similar to figures reported for U.S. males of roughly the same age; between 25% and 33% of all men aged 45-64 were current smokers in 1990-1991, while an even greater percentage (32% to 36%) of U.S. men of these ages were current smokers in 1983 and 1985.42 Current smoking among our cases was also similar to the Washington State series, as 29% of their cases were current smokers at interviews held an average of 5 months after diagnosis. 12 ' 22 From our descriptive analyses, then, smoking patterns among our PALS did not seem to differ markedly from the U.S. adult male population or from Kamel et al's ALS series. 23 However, smoking cannot be eliminated as a risk factor for ALS; more research into this area is required before a definitive answer can be reached.…”

Section: History Of Tobacco and Alcohol Usementioning

confidence: 52%

“…1° Some of the symptoms that can be treated palliatively include fatigue, dysphagia (i.e., difficulty swallowing), muscle spasticity, emotional lability, 3,4 sleeping problems, pain, depression, and sialorrhea (i.e., drooling). Death is usually the result of respiratory failure, 3 ' 4 and patient survival averages 1.5 to 2 years following diagnosis 0 -1 2 and 2.5 to 3 years 4 [10][11][12][13][14] following the appearance of the initial symptom.…”

Section: Clinical Features Of Alsmentioning

confidence: 99%

Case Series Investigation of Amyotrophic Lateral Sclerosis (ALS) Among Former Kelly Air Force Base Workers

Wackerman¹,

Shanklin²,

McGriff³

et al. 2005

PsycEXTRA Dataset

View full text Add to dashboard Cite

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

show abstract

“…Several diagnostic criteria have been devised for ALS [2,11,12]; however, most of them have been used in single studies and none has undergone a formal validation process, which prevents meaningful comparisons across studies. The El Escorial criteria (ECC) are the only diagnostic criteria having widespread use and has being assessed for validity and reliability [13].…”

Section: Diagnosis Of Alsmentioning

confidence: 99%

127th ENMC International Workshop: Implementation of a European Registry of ALS Naarden, The Netherlands, 8–10 October 2004

Beghi

2006

Neuromuscular Disorders

View full text Add to dashboard Cite

Prognosis in amyotrophic lateral sclerosis

Cited by 403 publications

References 52 publications

Kinesin-associated protein 3 (KIFAP3) has no effect on survival in a population-based cohort of ALS patients

Kinesin-associated protein 3 (KIFAP3) has no effect on survival in a population-based cohort of ALS patients

Case Series Investigation of Amyotrophic Lateral Sclerosis (ALS) Among Former Kelly Air Force Base Workers

127th ENMC International Workshop: Implementation of a European Registry of ALS Naarden, The Netherlands, 8–10 October 2004

Contact Info

Product

Resources

About